Global HIV Treatment Access Disruption: US Funding Withdrawal from South Africa and Cascading Public Health System Vulnerability Assessment

Executive Summary

The Trump administration's phased termination of PEPFAR funding for South Africa, confirmed by the State Department in June 2026, is translating a bilateral political dispute into a public health crisis with cross-continental consequences. US HIV funding to South Africa declined from $456 million in 2024 to approximately $25 million allocated so far in the current fiscal year, according to Politico's June 2026 reporting. The withdrawal does not merely threaten 8 million patients on antiretroviral therapy: it compounds an active Ebola emergency across the region, degrades the disease-surveillance infrastructure that the CDC was contracted to maintain across 60 country offices, and accelerates the conditions for drug-resistant tuberculosis rebound. Both the health security and geopolitical dimensions of this decision are mutually reinforcing in ways that extend well beyond South Africa's borders.

The Treatment Continuity Cliff

South Africa has approximately 8 million people living with HIV, according to UNAIDS, and has made substantial strides in treatment, with a majority of the population on antiretroviral drugs. That achievement is precisely what makes the funding withdrawal so consequential: the progress is real, the population dependent on sustained drug supply is enormous, and the margin for disruption is narrow.

Modeling published in PMC uses 7.4 million adults with prevalent HIV as its baseline, applying 2024 HIV care continuum data: 410,398 undiagnosed, 1,414,662 diagnosed but not on ART, and 5,574,940 diagnosed and on ART. Of those on treatment, the overwhelming majority are virally suppressed. That suppression is not self-sustaining, it requires uninterrupted drug procurement, clinic staffing, and laboratory monitoring, all of which PEPFAR has historically underwritten at the margin.

Research published in medrxiv found that over the term of the current US administration, 2025-2028, the cessation of PEPFAR funding in South Africa without replacement of services by the South African government would increase expected new HIV infections in adults between 29-57% and AIDS-related deaths by 33-38%, returning to levels similar to those estimated in 2017 for HIV infections and 2013 for AIDS deaths, thereby undoing more than a decade of progress.

The economic implications translate directly from the clinical ones. Sustaining PEPFAR-supported services without US backing would cost an additional $620 million to $1.4 billion between 2025 and 2028. That cost is not theoretical: it represents the minimum investment required to prevent the epidemiological reversal projected by multiple modeling teams. For a government already running a constrained fiscal envelope, the math is unforgiving. The interplay between treatment discontinuation and drug resistance is particularly dangerous because the costs externalize rapidly, drug-resistant strains cross borders, affecting regional neighbors and, eventually, global travelers.

The Drug-Resistance Feedback Loop

South Africa already carries one of the world's heaviest burdens of multidrug-resistant and extensively drug-resistant tuberculosis. HIV co-infection is a documented driver of resistance acquisition. Research published in The Lancet Microbe established that South Africa has a high burden of rifampicin-resistant tuberculosis, with increasing rifampicin-monoresistant tuberculosis over time, and that resistance acquisition during first-line tuberculosis treatment could be a key contributor, with HIV potentially increasing the risk of acquiring rifampicin resistance.

The mechanism is well characterized: patients whose HIV is insufficiently controlled have impaired immune responses, suffer more frequent TB co-infection, and are more moderate-to-high confidence to develop resistance when TB treatment is incomplete or inconsistent. Disrupting ART continuity for even a fraction of the 5.57 million people currently on treatment does not merely affect those individuals, it seeds a resistance reservoir that will cost far more to treat.

A PMC impact assessment found that TB services and research have faced significant instability since the 90-day stop-work orders were issued in late January 2025, affecting all programmes funded by CDC, USAID, and PEPFAR, followed by the termination of all USAID-funded programmes in South Africa in late February.

A key example of infrastructure at risk is the EDR Web system, vital to South Africa's efforts in controlling drug-resistant TB. The broader geopolitical and economic implications include the real possibility that drug-resistant TB strains circulating in an under-surveilled South African system reach neighboring countries through the extensive SADC regional labor migration networks, compounding the existing Ebola emergency with a second, slower-moving pathogen risk.

The Regional Health Security Architecture Under Stress

The HIV withdrawal does not stand alone. The New York Times reported in June 2026 that the State Department proposal would effectively shut the CDC out of overseeing many global health programs and shift control of funds and decisions to State, with CDC potentially closing approximately a third of its 60 country offices within three years. These offices perform functions well beyond PEPFAR: childhood immunization support, laboratory network strengthening, and critically, surveillance for emerging infectious diseases.

The 2026 outbreak of Ebola virus disease in DR Congo and Uganda, caused by Bundibugyo virus, represents one of the most consequential epidemic emergencies in Africa, and is particularly concerning because of its epidemiological and operational complexity, with 129 confirmed cases, over 1,000 suspected cases, and 246 suspected deaths reported as of late May.

No medical countermeasures currently exist against the Bundibugyo virus.

WHO and Africa CDC declared the outbreak a Public Health Emergency of International Concern and a Public Health Emergency of Continental Security, respectively. The broader geopolitical and strategic implications include a scenario where US-funded surveillance nodes, the same infrastructure being wound down under the PEPFAR restructuring, are precisely the early-warning systems that would otherwise detect and characterize cross-border Ebola transmission. The resulting spillover from HIV funding withdrawal affects not only HIV outcomes but the continent's general capacity to contain novel pathogen spread.

The ProPublica investigation published in 2026 documented a parallel dynamic in Uganda, where the US secured data-access conditions as part of a new bilateral health agreement: the country faces approximately 160,000 new HIV infections per year even with existing programs. The interplay between US geopolitical leverage over data sovereignty and health funding terms establishes a precedent, documented in Uganda's case, that is moderate-to-high confidence to shape how South Africa's own renegotiation proceeds.

The Self-Reliance Argument And Its Limits

The State Department's publicly stated rationale rests on two pillars: South Africa is a middle-income country capable of self-funding its health programs, and US funding should condition on policy compliance. South Africa, which has approximately 8 million people living with HIV per UNAIDS, has made great strides in treatment, with a majority of the population on antiretroviral drugs. The government funds antiretroviral procurement entirely from domestic resources, according to South Africa's health ministry, as reported by the BBC.

This framing, however, elides a structural asymmetry. South Africa's HIV burden is proportionally the largest in the world. Sub-Saharan Africa accounts for 77% of weekly global new HIV infections occurring among adolescent girls and young women, while only 1% of annual global health spending is available for the region. The US contribution was not program management overhead that can be absorbed through efficiency gains, it funded specific service delivery nodes, testing programs, prevention infrastructure, and data systems whose closure creates immediate service gaps.

MSF, the international aid agency, says that although it was somewhat shielded from US aid cuts, costs have increased due to partner organizations that helped with feeding schemes or outreach work being forced to close overnight. MSF international president Javid Abdelmoneim stated explicitly: "We can't fill the gaps as MSF and neither can any humanitarian organisation."

The lenacapavir development, while genuinely significant, illustrates the gap between the prevention and treatment financing problems. The Global Fund has reallocated $29 million of existing funding to provide approximately 500,000 person-years of lenacapavir in 2026 and 2027 at a subsidized drug price of $60 per person per year to the South African HIV program. The reallocation is a partial solution, available only because the Global Fund drew down existing reserves, it does not represent new global health funding but a redistribution of a shrinking pool.

Counterarguments

1. South Africa's government funds antiretroviral procurement independently, making the "treatment cliff" less steep than modeled. South Africa's health ministry confirmed to the BBC that life-saving antiretroviral drugs are funded entirely separately from PEPFAR, with most coming from government sources. This is an important corrective to the most severe presentations of the crisis: the patients currently on ART are not immediately losing drug access. The PEPFAR funding loss primarily affects the service delivery ecosystem, testing, outreach, healthcare worker salaries, data systems, and prevention programs, rather than the drug supply itself. A more calibrated reading of the evidence suggests the near-term mortality risk is concentrated in the untreated and newly infectious populations rather than in those already on suppressed regimens. This does not eliminate the long-term modeled risk, but it compresses the immediate humanitarian emergency.

2. The "self-reliance" pathway has worked before, and prior PEPFAR transition experience is instructive but not determinative. South Africa previously managed a partial PEPFAR transition in 2013-2017, absorbing a shift from clinical care to technical assistance. Research from the Western Cape published in PMC found that the earlier transition was associated with patient losses to follow-up but did not produce the severe reversal some modelers predicted at the time. The current situation differs in scale and speed, the 2013-2017 transition was managed over years with jointly planned timelines, while the 2025-2026 drawdown has been abrupt, but historical precedent suggests South African health institutions have greater adaptive capacity than worst-case models assume. Decision-makers should weight the managed-transition scenario more heavily than models calibrated to assume zero government adaptation.

3. China's entry as an alternative funder has been underweighted in published analyses. Context News reported in late 2025 that China pledged $3.5 million for South Africa's HIV response following US cuts. The figure is small relative to the gap, but it signals a geopolitical dynamic that most epidemiological models ignore entirely: the US withdrawal creates political space for Chinese and other non-Western funders to deepen health partnerships on terms favorable to those governments. If Chinese investment scales, which remains uncertain and unverified at this writing, the humanitarian projections require revision downward while the geopolitical implications of US influence displacement require revision upward. The picture is genuinely mixed, and analyses that treat the donor landscape as static are understating this variable.

Indicators To Watch

Decision Relevance

Scenario A (~55-60%): Managed deterioration with partial domestic substitution. South Africa's government announces partial HIV budget supplements, the Global Fund provides further bridge financing, and some testing and outreach functions are contracted to local NGOs. Treatment for the currently suppressed cohort is largely preserved. New infections rise materially above baseline but the worst modeled outcomes do not materialize within the 2025-2028 window. CDC country office restructuring proceeds but Africa-based surveillance functions are partially absorbed by Africa CDC's continental infrastructure. Recommended: Organizations with supply chain exposure to Sub-Saharan Africa healthcare markets should map their dependence on PEPFAR-supported logistics nodes and begin qualifying alternative procurement channels now. Pharmaceutical manufacturers of second-line antiretrovirals should anticipate a shift in payer mix from US-backed programs to Global Fund and domestic tenders.

Scenario B (~30-35%): Accelerated epidemiological reversal with regional health security spillover. South Africa's government fails to close the funding gap within the 2025-2028 window. Testing volumes fall sharply, treatment program attrition accelerates, and viral rebound among previously suppressed patients triggers a measurable drug-resistance amplification event. Simultaneously, the Ebola outbreak in DRC and Uganda exploits weakened surveillance networks to reach SADC countries. Recommended: Organizations with operations or investments in Southern Africa should activate enhanced health security protocols for employees in the region, accelerate supply chain diversification away from South Africa as a logistics hub, and hedge against sovereign credit risk in a scenario where South Africa faces simultaneous health, fiscal, and investment headwinds.

Scenario C (~10%): US policy reversal or major alternative donor mobilization. Congressional pressure, a shift in the bilateral political dispute, or a large-scale Chinese or European health funding commitment reverses or substantially offsets the PEPFAR withdrawal. Epidemiological trajectories stabilize. Recommended: Monitor Congressional PEPFAR appropriations debates and Africa-focused diplomatic signals from Beijing and Brussels. A reversal would represent a re-entry signal for health sector investment in South Africa and a validation of the Global Fund's role as a structural backstop for sovereign health financing.

Securitization Theory Analysis

Securitizing Actor: The Trump administration and the State Department are the primary securitizing actors, but operating in an unusual direction: they are de-securitizing a previously securitized domain. PEPFAR was framed by the Bush administration in 2003 as a national security imperative, a program credited by the New York Times with saving 26 million lives, and has maintained bipartisan securitization through four administrations. The current administration has inverted that frame, treating the program as a mechanism for political coercion over Pretoria rather than a US security asset.

Referent Object: The referent objects in tension are two: (1) the South African and broader African patient population whose survival depends on ART continuity, and (2) what the Trump administration frames as US taxpayer interests and conditions of bilateral policy compliance from recipients.

Existential Threat Construction: The State Department official cited by Politico deployed the language of "self-reliance" and "middle-income country" status to reframe South Africa from a legitimate aid recipient to a capable actor choosing dependency. The Trump executive order, cited by both BBC and Politico, framed South Africa as a country engaged in discriminatory practices against Afrikaners and hostile geopolitical postures, including the ICJ case against Israel, constituting a threat to US values sufficient to justify aid termination.

Target Audience: The primary target audience is domestic US, conservative voters and donors who view conditionality-based foreign aid reform favorably. The secondary audience is other PEPFAR-recipient governments being signaled that US aid is now conditioned on bilateral compliance across a broader set of political issues.

Extraordinary Measures: The termination of PEPFAR for a specific country based on non-health political disputes is itself the extraordinary measure. It breaks from 22 years of bipartisan norm under which PEPFAR funding was treated as humanitarian and health-security policy insulated from bilateral political disputes.

Classification: SECURITIZED — HIV/AIDS response has been re-securitized as a tool of bilateral political leverage rather than de-politicized humanitarian action, with extraordinary measures (funding termination, conditional data-access requirements documented by ProPublica in Uganda) now operational.

Process Tracing Analysis

Cause and Outcome: The cause is the Trump administration's February 2025 executive order directing agencies to halt aid to South Africa absent policy compliance. The outcome is the progressive collapse of US HIV program funding, from $456 million in 2024 to $25 million in 2026, with confirmed "phased drawdown" now underway.

Causal Mechanism Chain: The executive order triggered a 90-day aid freeze in January 2025, affecting all PEPFAR programming. A bridge plan negotiated in October 2025 provided temporary reprieve. South Africa did not alter its policies on Black Economic Empowerment, its ICJ position on Gaza, or its relationship with Iran, the three conditions cited in US communications per Politico. In June 2026, the State Department confirmed the drawdown, citing "South Africa's failure to make demonstrable progress on policy requests." The State Department simultaneously proposed restructuring CDC's PEPFAR authority to State, creating a governance change that reduces the technical independence of the program's implementation.

Evidence Assessment:

• Hoop test (necessary): South Africa's refusal to meet US bilateral policy conditions must be confirmed for the mechanism to hold. The South African government's documented rejection of the administration's Afrikaner genocide claim and continuation of BEE policy, confirmed by both BBC and Politico, passes this test.
• Smoking gun (highly diagnostic): The State Department official's on-record statement to Politico confirming that the "phased drawdown" decision follows "South Africa's failure to make demonstrable progress on policy requests" is highly diagnostic, it directly names the political mechanism rather than a health or fiscal rationale.
• Straw-in-the-wind: The funding trajectory from $456M to $25M across two years is consistent with politically motivated termination rather than programmatic phase-out, though a defender could argue it reflects general foreign aid reform.

CAUSAL_MECHANISM_STRENGTH: STRONG — The smoking gun evidence from the State Department confirmation, combined with the documented bilateral political dispute as the stated rationale, makes the causal mechanism well-supported, though the epistemic limitation is that full internal decision documentation is not publicly available.

Constructivism Lens Analysis

Actor Identities: The Trump administration projects the identity of a sovereignty-asserting power correcting a decades-long pattern of unconditioned "global welfarism." South Africa projects the identity of a post-colonial sovereign state asserting the right to set domestic economic policy (BEE) and independent foreign policy (ICJ) without being subject to donor conditionality on unrelated matters. These identity projections are genuinely in conflict, not merely a negotiating posture.

Operative Norms: Two norms are colliding. The first is the post-PEPFAR humanitarian norm: bilateral aid for infectious disease control should be insulated from political conditionality because the referent object (the patient population) is distinct from the government. This norm governed PEPFAR's bipartisan architecture for 22 years. The second is an emerging sovereignty-of-the-donor norm: donor states have the right to condition aid on recipient compliance across all bilateral issues, including domestic policy. The US is actively asserting the second norm, challenging the first.

Intersubjective Meaning: The shared meaning of PEPFAR is being actively contested. For the global health community, PEPFAR is what the NYT calls "a program credited with saving 26 million lives" — its meaning is humanitarian and security-grounded. For the current US administration, it has been reconstructed as a foreign policy instrument subject to full bilateral conditionality. South Africa's health ministry, in asserting that ARV drug supply is domestically funded, is attempting to narrow the shared meaning of the "threat" — reducing it from an existential crisis to a manageable gap, to resist political capitulation.

Norm Lifecycle Stage: The humanitarian-insulation norm governing PEPFAR is in active Erosion/Contestation. The Trump administration's actions have demonstrably violated it, but it has not been replaced by an accepted alternative norm; most donors, including the EU and Global Fund, continue to operate under the old paradigm.

Norm Lifecycle: EROSION

Analytical Limitations

• South Africa's domestic HIV budget supplementary capacity is not precisely quantifiable from open-source material; the government's actual fiscal response in the second half of 2026 will determine whether the worst modeled outcomes materialize and is the single most important variable this assessment cannot forecast.
• The Lancet modeling studies reviewed by this assessment use 2024 care cascade data; current clinic-level disruption data from PEPFAR-supported facilities in 2026 is fragmentary, with HealthBeat's April 2026 reporting confirming declining HIV testing rates but not providing a nationally representative picture.
• China's HIV financing intentions in South Africa are based on a $3.5 million pledge, a signal, not a commitment to scale, and no confirmed follow-on commitment has been verified as of this writing; the geopolitical displacement dynamic is real but its magnitude is indeterminate.
• The drug-resistant TB amplification pathway involves a multi-year lag between viral rebound and measurable resistance acquisition at the population level, meaning clinical evidence of this feedback loop will not be available for 18-36 months even if the mechanism is already operating.
• Modeling studies estimating 565,000 additional infections and 601,000 deaths by 2034 at PEPFAR zero assume no domestic substitution; this represents a floor scenario. The actual outcome will depend on the degree of South African government response and alternate donor mobilization, both of which remain genuinely uncertain.